RxDoctor Payments Data

John Fontenot, MD

Internal Medicine · Mamou, LANPI 1801822044

Payments from drug & device makers

$396in general payments, 2019–2025

Across 17 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$69
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$46
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$35
  • Amgen$32
  • Ardelyx, Inc.$32
  • Neurocrine Biosciences, Inc.$32
  • plus $149 from 7 others

What the payments were for

  • Food & beverage$396100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$396 in reported general payments places this provider in the 50th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$10,862
Medicare patients
159
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$64,522
TrulicityDulaglutide55$52,426
JanuviaSitagliptin Phosphate86$51,532
EliquisApixaban93$42,243
LinzessLinaclotide60$38,194
MounjaroTirzepatide24$31,770
TradjentaLinagliptin42$26,790
JardianceEmpagliflozin43$25,646
EntrestoSacubitril/Valsartan35$20,988
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$19,802
ElmironPentosan Polysulfate Sodium13$13,259
Combivent RespimatIpratropium/Albuterol Sulfate19$10,479
Breo ElliptaFluticasone/Vilanterol25$10,294
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen458$10,157
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$9,243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$64,52262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Mamou

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →